Apollo Therapeutics Completes $145 Million Financing Led by Affected person Sq. Capital to Increase and Advance Portfolio-Primarily based Drug Improvement

Proceeds to assist speedy development of pipeline with over 15 therapeutic applications at the moment in improvement throughout oncology, main inflammatory issues and uncommon illness

Firm to broaden with U.S. operations in Boston space and pursue collaborations globally with main educational establishments

CAMBRIDGE, England, Jun 17, 2021–(BUSINESS WIRE)–Apollo Therapeutics, a portfolio-based biopharmaceutical firm quickly advancing probably transformative therapies primarily based on breakthrough discoveries, has accomplished a $145 million (over £100 million) financing. The financing was led by Affected person Sq. Capital, which can take a controlling place within the enterprise, with participation from further buyers together with Rock Springs Capital, Reimagined Ventures and UCL Expertise Fund. Proceeds from the funding will assist development of Apollo’s sturdy pipeline into improvement, enlargement of the corporate’s operations together with institution of a presence within the Boston, MA space and pursuit of recent collaborations globally.

This press launch options multimedia. View the complete launch right here:

“5 years in the past, Apollo’s modern mannequin was created by three world-leading universities Cambridge, Imperial Faculty London and College Faculty London forming a three way partnership with international pharma companions AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation to effectively advance breakthrough discoveries which have the potential to be transformative therapies for sufferers,” mentioned Dr. Richard Mason, CEO of Apollo. “In that point, Apollo has exceeded conventional development benchmarks – quickly constructing a pipeline of over 15 promising applications. There’s vital alternative forward of us to deliver new therapies to market as our lead applications transfer into scientific improvement. We are going to look to construct on our current collaborations, foster new relationships with further prime teachers all over the world and in-license drug candidates from new companions.”

Added Jim Momtazee, Managing Companion of Affected person Sq. and member of Apollo’s Board of Administrators, “For the previous twenty years, I’ve pursued a thesis in therapeutics of backing excellent groups and constructing multi-product portfolios in vital areas of medication. Affected person Sq. continues to be very obsessed with that enterprise mannequin. We’re extraordinarily excited to accomplice with the staff at Apollo, as we see large potential of their product portfolio and their novel partnership method with three of the world’s prime educational establishments pursuing a few of the most modern science globally. We look ahead to working carefully with the Apollo staff to broaden their attain globally and to deliver a variety of probably life-changing medicines to sufferers.”

Rooted in Collaboration

Apollo was initially established in late 2015 as a novel three way partnership between the College of Cambridge, Imperial Faculty London (then subsequently IP Group Plc), College Faculty London, AstraZeneca, GlaxoSmithKline (GSK) and Johnson & Johnson Innovation. Apollo was set-up to bridge the hole from deep educational science to affected person profit in probably the most capital and time environment friendly manner attainable. By fostering relationships with prime educational scientists and leveraging insights from strategic companions with late-stage improvement and business experience, Apollo seeks to develop therapeutics which have transformative potential above the present normal of care. The corporate evaluates breakthrough scientific discoveries throughout a number of standards, together with having a compelling and testable organic speculation or having a differentiated mechanism or know-how in comparison with different therapeutics in improvement or in the marketplace. Every of the three way partnership founders retains a minority stake within the firm submit financing.

Effectivity in Improvement

To advance applications effectively, Apollo leverages a portfolio-based mannequin with a centralized staff of drug improvement ‘architects’ working alongside asset-level groups of subject material consultants. Collectively, these groups are capable of rigorously consider therapeutic applications in an goal, data-driven method – prioritizing essential experiments to de-risk applications early. The corporate is ready to comprehensively consider applications, whereas committing minimal spend till demonstrating organic validation. This capital effectivity permits Apollo to give attention to scaling a strong and probably transformative pipeline, with over 15 therapeutic applications in improvement at present throughout oncology, main inflammatory issues and uncommon illness.

Constructing Upon Success

With proceeds from this financing, Apollo plans to advance its lead therapeutic applications into scientific improvement in addition to determine new applications. As well as, the corporate plans to broaden its UK operations within the Cambridge space, and in america with a brand new facility in Boston/Cambridge. Apollo’s rising staff will even discover further collaborative relationships with main educational researchers all over the world.

Established Management

Apollo is led by Dr. Richard Mason, who was not too long ago appointed as chief government officer. Dr. Mason has over 20 years’ expertise within the biotech {industry}, together with serving as the top of the Johnson & Johnson Innovation Middle in London. Earlier than this, he was CEO of novel anticoagulant antibody firm XO1 till the sale of the corporate. Beforehand, Dr. Mason was the chief management staff member answerable for technique and enterprise improvement at listed corporations BTG and Cambridge Antibody Expertise the place he led quite a few M&A and partnering transactions. He obtained levels in drugs from St. Bartholomew’s Hospital Medical Faculty and immunology from College Faculty London and skilled in inner drugs in London.

At the side of the financing, Jim Momtazee, Managing Companion of Affected person Sq. Capital, will be a part of Apollo’s Board of Administrators. Previous to Affected person Sq., Mr. Momtazee spent over 21 years at KKR, the place he helped set up the agency’s well being care {industry} group in 2001 and subsequently was head of the Americas Well being Care Funding Crew for over 10 years. Mr. Momtazee has spent years on the board of administrators of Jazz Prescription drugs, HCA, PRA Well being Sciences and BridgeBio Pharma, amongst different corporations. Jazz Prescription drugs and BridgeBio Pharma are each examples of the multi-product thesis pursued by the Affected person Sq. staff, and that collected expertise will likely be notably additive in supporting the expansion and enlargement of Apollo within the years to return.

Dr. Richard Butt who has been with Apollo since its inception, will function the corporate’s chief scientific officer. Jamie Heath will be a part of the corporate as chief monetary officer and Arjun Krishnan as chief enterprise officer. Dr. Ian Tomlinson who beforehand chaired Apollo’s funding committee, will be a part of the Board as a non-executive director.

About Affected person Sq. Capital

Affected person Sq. Capital is a devoted well being care funding agency that companions with best-in-class administration groups whose merchandise, companies and applied sciences enhance well being. We make the most of our deep {industry} experience, our broad community of relationships and a real partnership method to make investments in corporations that may develop and thrive. We consider within the energy these corporations have to enhance affected person lives, strengthen communities and create a more healthy world. Affected person Sq. is purpose-built by a staff of industry-leading executives, differentiated by the depth of our focus in well being care, the breadth of our well being care investing expertise, and the community we are able to activate to drive differentiated outcomes. Most significantly, sufferers are squarely on the middle of all that we do. For extra info, go to

About Apollo Therapeutics

Apollo Therapeutics is a portfolio-based biopharmaceutical firm quickly advancing a strong pipeline of doubtless transformative therapeutic applications primarily based on breakthrough discoveries. By way of deep relationships with world-leading scientists and inventors, the corporate identifies applications with sturdy organic hypotheses and potential to turn into significant new remedy choices. Apollo’s mannequin combines drug improvement ‘architects’ and deep subject material consultants to construct an expansive and de-risked pipeline in oncology, main inflammatory issues and uncommon illness. Apollo was fashioned in late 2015 as a three way partnership between three main educational establishments – College of Cambridge, Imperial Faculty London and College Faculty London, and three pharmaceutical and healthcare corporations – AstraZeneca, GlaxoSmithKline (GSK) and Johnson & Johnson Innovation – JJDC, Inc. For extra info, go to

View supply model on


Media Contact (Apollo Therapeutics)
Tyler Gagnon
Canale Communications
(508) 904-9446

Media Contact (Affected person Sq. Capital)
Zach Kouwe/Shree Dhond/Doug Allen
Dukas Linden Public Relations;;
(212) 704-7385

Related posts

U.Okay. to Begin Talks With EU on Finance Cooperation This Week


Canacol Power Ltd. To Announce First Quarter 2021 Monetary Outcomes on Thursday, Could 13, 2021; Maintain Convention Name on Friday, Could 14, 2021


Evaluation: Chasing yield, U.S. personal fairness corporations nudge up danger on insurers


Leave a Comment